First-line treatment in metastatic colorectal cancer: Important or crucial?
- 1 October 2017
- journal article
- editorial
- Published by Elsevier BV in European Journal of Cancer
- Vol. 84, 363-366
- https://doi.org/10.1016/j.ejca.2017.09.001
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)European Journal of Cancer, 2017
- Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal CancerJAMA, 2017
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trialThe Lancet Oncology, 2016
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnnals of Oncology, 2016
- Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)European Journal of Cancer, 2015
- Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestAnnals of Oncology, 2015
- Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System DatabaseJournal of Clinical Oncology, 2015
- Progression-Free Survival: Helpful Biomarker or Clinically Meaningless End Point?Journal of Clinical Oncology, 2015
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2014
- Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line TrialsClinical Cancer Research, 2013